Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

Stopped early

Conditions studied: Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging

In brief

This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and the University of Alabama at Birmingham (UAB) Hospital). The primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing CIPN during chemotherapy.

Key facts

Study ID
NCT04932031
Run by
Sapere Bio
People needed
123
Starts
2022-05-25
Expected to finish
2023-11-01
Last updated by the study team
2023-11-03

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.